<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110963">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01924065</url>
  </required_header>
  <id_info>
    <org_study_id>ozaydin291</org_study_id>
    <nct_id>NCT01924065</nct_id>
  </id_info>
  <brief_title>Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation</brief_title>
  <acronym>AFTER-CV</acronym>
  <official_title>Does Cardioversion of Atrial Fibrillation Increase the Risk of Stroke and Silent Cerebrovascular Thromboembolism? Comparison of the Two Cardioversion Methods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suleyman Demirel University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suleyman Demirel University</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with atrial fibrillation undergoing cardioversion will be randomized to undergo
      transesophageal echocardiography or they will receive warfarin for 4 weeks with an
      international normalized ratio (INR) value between 2.0-3.0.

      If thrombus is detected in left atrium or in left atrial appendage, no cardioversion will be
      performed. Other patients in the both groups will undergo electrical cardioversion. All
      patients will have neurological examination and diffusion magnetic resonance imaging (MRI)
      at baseline and at postprocedural 7th day. Clinical and subclinical cerebral thromboembolic
      events detected by diffusion MRI will be recorded. Any bleeding events during this period
      will also be recorded.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Stroke</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ischemic or hemorrhagic strokes will be recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>silent cerebral thromboemboli</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>silent cerebral thromboemboli detected by diffusion magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Cardioversion</condition>
  <condition>Cerebrovascular Stroke</condition>
  <arm_group>
    <arm_group_label>Transesophageal Echocardiography group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm includes the patients with atrial fibrillation who undergo  transesophageal echocardiography-guided cardioversion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm includes the patients with atrial fibrillation who take warfarin four weeks before electrical cardioversion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardioversion</intervention_name>
    <arm_group_label>Transesophageal Echocardiography group</arm_group_label>
    <arm_group_label>Warfarin Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <arm_group_label>Warfarin Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the age of more than 18 years who are planned to undergo electrical
             cardioversion

        Exclusion Criteria:

          -  Urgent cardioversion

          -  Patients who have implanted pace-makers or other metal devices

          -  Claustrophobia

          -  Hematological disorders enabling patients to receive anticoagulant agents

          -  Atrial fibrillation secondary to temporary causes.

          -  Serious rheumatic heart valve disease

          -  Hyperthyroidism

          -  History of malignancy

          -  Left atrium diameter &gt; 55 mm

          -  Ejection fraction &lt; 0.25
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Ozaydin, Proffesor,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Suleyman Demirel University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Suleyman Demirel University</name>
      <address>
        <city>Isparta</city>
        <state>Mediterranean Region</state>
        <zip>32260</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdullah Dogan, Proffesor,MD</last_name>
      <phone>+0902462324479</phone>
      <phone_ext>1140</phone_ext>
      <email>adogan35@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Mehmet Ozaydin, Proffesor,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ä°brahim Ersoy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>August 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Suleyman Demirel University</investigator_affiliation>
    <investigator_full_name>Mehmet Ozaydin, MD</investigator_full_name>
    <investigator_title>MD, Professor in Cardiology</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation, conversion, stroke</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
